Lord, Abbett & Co
CADX

Lord, Abbett & Co’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Lord, Abbett & Co’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-906,907
Closed -$8.21M – 1149
2013
Q4 		$8.21M Buy
906,907
+455,801
+101% +$3.29M 0.02% 710
2013
Q3 		$2.85M Sell
451,106
-392,851
-47% -$2.5M 0.01% 915
2013
Q2 		$5.76M Buy
+843,957
New +$5.88M 0.01% 770

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lord, Abbett & Co's CADX Position: Q1 2014 in Review

Lord, Abbett & Co sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 906,907 shares — an estimated $8.21M sold.

Lord, Abbett & Co first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $8.21M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Lord, Abbett & Co reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 906,907 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $8.21M.
  • Lord, Abbett & Co first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Lord, Abbett & Co's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $8.21M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Lord, Abbett & Co's 13F filing for Q1 2014, filed 15 May 2014.